Collaborative drug discovery and development programs are, and will be, a key element of our present and future strategy.
Thrombotargets is a group of innovative Biotech companies continuously growing and rapidly evolving through a constant setting of Strategic Alliances in a wide range of Biotechnological areas.
Thrombotargets pipeline is composed of innovative drug candidates in the fields of Haemostasis and Thrombosis. Some of these compounds, as for instance our recently Orphan Drug designated “TT-103MH topical antihemorrhagic recombinant protein”, are available for licensing out. We also have new anticoagulants, antifibrinolytics, antiplatelet agents and are working on innovative gene therapies for the treatment of coagulation disorders.
is the High Throughput Screening Platform for Pathway Activity (HTS-PA) that has allowed Thrombotargets to discover such a cutting edge pipeline in less than two years. The platform is now available as a HTS service, therefore don't hesitate to contact us to get further information about this advantageous service.
Thrombotargets has set up alliances and agreements with many public and private research centres, with hospitals and universities focused in different knowledge areas and exclusive technologies (i.e. cardiovascular research, clinical trials in haemostasis and coagulation areas, focused libraries design and synthesis, biotechnology skills such as biological products production and process development, etc).
Thrombotargets has also set up collaborative agreements with many companies working on different complementary fields such as screening compounds & providers for medicinal chemistry services, bioinformatics, complementary biotechnology companies, pre-clinical & clinical trials CRO and many more.